Clinical trials: Endometrial Carcinoma (EC)
Complex Atypical Hyperplasia, Endometrial Cancer
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial…
- Trial name
- NCT05483023
- Testing
- 18F-fluorofuranylnorprogesterone PET / MRI
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ovarian Cancer, Endometrial Cancer
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
This is a Phase II clinical trial evaluating the benefit from therapy with vintafolide in participants with advanced ovarian and endometrial cancers.
- Trial name
- NCT00507741
- Testing
- Vintafolide, Ertafolide
- Volunteers
- 49 people
- Sponsor
- Endocyte
Endometrial Carcinoma (EC)
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in…
- Trial name
- SHORTEN (NCT07675733)
- Testing
- Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer
The investigators hypothesize that SLND (unlike lymphadenectomy) decreases complications such as hemorrhage, lower extremity lymphedema and lymphocyst formation while enhancing quality of life in EC patients with low risk for…
- Trial name
- NCT02834988
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Miami
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Endometrial Cancer
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per…
- Trial name
- XPORT-EC-042 (NCT05611931)
- Testing
- Selinexor
- Where
- 191 sites in United States, Australia and 15 more
- Volunteers
- 257 people
- Sponsor
- Karyopharm Therapeutics Inc
Endometrial Carcinoma (EC), pMMR
IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER
Endometrial carcinoma (EC) represents the most common gynecological malignancy in developed countries. Despite therapeutic advances, patients with advanced or recurrent disease still have a poor prognosis, with high recurrence…
- Conditions
- Endometrial Carcinoma (EC), pMMR, DMMR Cancer
- Trial name
- DEMETER (NCT07374809)
- Testing
- DNA methylation profiles
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Endometrium Cancer
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen.
- Trial name
- NCT06192017
- Testing
- WomEC
- Where
- 26 sites in Spain
- Volunteers
- 1,950 people
- Sponsor
- MiMARK Diagnostics, S.L.
Abnormal Uterine Bleeding (AUB), Endometrial Cancer
Endometrial Cancer Vaginal Fluid Specimen Collection Study
This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
- Conditions
- Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
- Trial name
- ENVISION (NCT07544680)
- Where
- 5 sites in United States
- Volunteers
- 4,200 people
- Sponsor
- Exact Sciences Corporation
Neoplasms, Endometrial
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants.
- Trial name
- NCT07108270
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer, Cervical Cancer
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC).
- Trial name
- NCT06925724
- Testing
- Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Cancer
Tirzepatide in the Treatment of Endometrial Cancer
This study is looking for a better way to treat pre-cancer or early-stage cancer in the lining of the uterus in women who are also overweight.
- Trial name
- TREAT-EC (NCT07605247)
- Testing
- Tirzepatide, LNG-IUD plus tirzepatide
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Endometrial Cancer
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer
The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).
- Trial name
- NCT07737795
- Testing
- OK-1 & Paclitaxel
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Oklahoma
Endometrial Cancer, Endometrial Carcinoma (EC)
Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer
This multicenter retrospective observational cohort study aims to evaluate the prognosis of patients with non-myoinvasive endometrial cancer harbouring high-risk molecular features by determining the rate of lymph node…
- Conditions
- Endometrial Cancer, Endometrial Carcinoma (EC), p53abn
- Trial name
- MyoNone (NCT07838207)
- Where
- Spain
- Volunteers
- 350 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Endometrial Cancer
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: mirvetuximab soravtansine (IMGN853) pembrolizumab
- Trial name
- NCT03835819
- Testing
- Pembrolizumab, IMGN853
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Endometrial Cancer, Endometrial Neoplasm
Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification
In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on…
- Trial name
- NCT07006103
- Volunteers
- 400 people
- Sponsor
- Hospital Italiano de Buenos Aires
Endometrial Carcinoma
Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
This phase I trial investigates the development of a new early detection test to reduce racial disparities in endometrial cancer death rates.
- Trial name
- NCT04474184
- Testing
- Biospecimen Collection, Focus Group, Survey Administration
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Sentinel Lymph Node Biopsy, MRI
The Combination of Preoperative MRI and SLN in the Surgical Management of CC and EC
The aim of the study was to evaluate the diagnostic value of MRI and/or SLN mapping alone or in combination in cervical (CC) and endometrial cancer (EC) patients.
- Trial name
- NCT05942170
- Testing
- ICG/ blue dye
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University